The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Cytokine Release Syndrome Treatment Market Become By 2030 Compared To 2026?
The cytokine release syndrome treatment market size has experienced rapid expansion in recent years. Its value is anticipated to rise from $1.42 billion in 2025 to $1.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.6%. The historical growth of this market can be linked to the progression in advanced immunotherapy treatments, an increase in CAR-T cell therapy adoption, the provision of corticosteroids for immune modulation, greater clinical awareness concerning cytokine storms, and enhancements in critical care infrastructure.
The market size for cytokine release syndrome treatment is projected to experience swift expansion over the coming years. This market is anticipated to reach $2.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. Several factors contribute to this growth during the projected period, including the increased adoption of next-generation immunotherapies, greater investments in cytokine modulation research, the expansion of oncology treatment facilities, a heightened emphasis on personalized immune management, and the creation of new anti-inflammatory biologics. Key trends for the forecast period encompass the increased utilization of IL-6 and IL-1 targeted therapies, a surge in the adoption of monoclonal antibodies for CRS management, the broadening of hospital-based CRS treatment protocols, the growing incorporation of early diagnostic monitoring, and enhanced supportive care management strategies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
What Influential Factors Are Boosting The Cytokine Release Syndrome Treatment Market Demand?
The projected expansion of the cytokine release syndrome (CRS) treatment market is anticipated to be fueled by the rising adoption of cancer therapies. This surge in cancer treatments stems from a global increase in cancer cases and innovations in diagnostic methods, facilitating earlier diagnosis and wider therapeutic possibilities. Furthermore, better patient survival rates and greater access to healthcare services further boost the demand for these treatments. Managing CRS typically includes supportive care, anti-cytokine medications, and continuous observation to control symptoms and lessen the inflammatory reactions resulting from cancer interventions. As an illustration, in May 2024, the UK’s National Health Service (NHS) reported that nearly 340,000 individuals began their initial cancer treatment during the period from April 2023 to March 2024. Moreover, urgent suspected cancer referrals reached an unprecedented level in March 2024, with 12,554 patients seen daily, surpassing the prior peak of 12,376 patients per working day recorded in July 2023. Consequently, the expanding scope of cancer treatments is a significant driver for the cytokine release syndrome treatment market.
What Segment Categories Are Evaluated In The Cytokine Release Syndrome Treatment Market Study?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
What Trends Are Affecting The Growth Of The Cytokine Release Syndrome Treatment Market?
Leading companies within the cytokine release syndrome treatment market are advancing drug delivery technologies, such as intravenous infusion, to enhance treatment precision, mitigate side effects, and improve patient outcomes. Intravenous infusion, when used in the treatment of cytokine release syndrome, enables rapid and accurate drug delivery into the bloodstream, thus ensuring swift therapeutic action. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, secured regulatory approval for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody, from the Ministry of Health, Labor, and Welfare, a Japan-based government authority, for managing cytokine release syndrome (CRS) provoked by various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) constitutes an additional approved use in addressing cytokine release syndrome (CRS) originating from cancer therapy. With this new approval, Actemra is now applicable as an anti-cytokine therapy for CRS resulting from cancer treatments extending beyond tumor-specific T-cell infusion therapy.
Who Are The Firms Contributing To The Cytokine Release Syndrome Treatment Market Ecosystem?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
Access The Complete Cytokine Release Syndrome Treatment Market Report:
Which Region Contributes The Most To The Cytokine Release Syndrome Treatment Market?
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Cytokine Release Syndrome Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Treatment Market 2026, By The Business Research Company
Drugs For Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model